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ORIGINAL ARTICLEHigh prevalence of blaOXA-23 in Acinetobacter spp. and detection
of blaNDM-1 in A. soli in Cuba: report from National Surveillance
Program (2010–2012)D. Quiñones1, I. Carvajal1, Y. Perez1, M. Hart2, J. Perez3, S. Garcia4, D. Salazar1, S. Ghosh5,6, M. Kawaguchiya5, M. S. Aung5 and
N. Kobayashi5
1) Tropical Medicine Institute ‘Pedro Kourí’, 2) ‘Hermanos Ameijeiras’ Hospital, 3) Pediátrico ‘J. M. Márquez’ Hospital, Havana City, 4) ‘V. I. Lenin’ Hospital,
Holguín, Holguín, Cuba, 5) Department of Hygiene, Sapporo Medical University School of Medicine, Sapporo, Japan and 6) Department of Biomedical Science,
Ross University School of Medicine, St Kitts, West IndiesAbstractAs a ﬁrst national surveillance of Acinetobacter in Cuba, a total of 500 Acinetobacter spp. isolates recovered from 30 hospitals between 2010
and 2012 were studied. Acinetobacter baumannii–calcoaceticus complex accounted for 96.4% of all the Acinetobacter isolates, while other
species were detected at low frequency (A. junii 1.6%, A. lwofﬁi 1%, A. haemolyticus 0.8%, A. soli 0.2%). Resistance rates of isolates were
34–61% to third-generation cephalosporins, 49–50% to β-lactams/inhibitor combinations, 42–47% to aminoglycosides, 42–44% to
carbapenems and 55% to ciproﬂoxacin. However, resistance rates to colistin, doxycycline, tetracycline and rifampin were less than 5%.
Among carbapenem-resistant isolates, 75% harboured different blaOXA genes (OXA-23, 73%; OXA-24, 18%; OXA-58, 3%). The blaNDM-1
gene was identiﬁed in an A. soli strain, of which the species was conﬁrmed by sequence analysis of 16S rRNA gene, rpoB, rpoB–rpoC and
rpoL–rpoB intergenic spacer regions and gyrB. The sequences of blaNDM-1 and its surrounding genes were identical to those reported for
plasmids of A. baumannii and A. lwofﬁ strains. This is the ﬁrst report of blaNDM-1 in A. soli, together with a high prevalence of OXA-23
carbapenemase for carbapenem resistance in Acinetobacter spp. in Cuba.
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
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nkobayas@sapmed.ac.jp (N. Kobayashi)IntroductionThe genus Acinetobacter includes opportunistic pathogens
capable of causing both community- and health care–associated
infections, and it has recently emerged as their major causew Microbe and New Infect 2015; 7: 52–56
w Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.nmni.2015.06.002because of its propensity to accumulate resistance to multiple
antimicrobial drugs [1]. Multidrug-resistant Acinetobacter bau-
mannii–calcoaceticus complex (A. baumannii–c complex) isolates
are increasingly reported worldwide; it is susceptible to an ‘old’
drug, colistin, which often remains as the only effective thera-
peutic option. Bacterial isolates showing carbapenem resistance
have been increasing as a result of acquisition of carbapenemase
belonging to classes A, B and D β-lactamases.
Class B β-lactamases, i.e. metallo-β-lactamases (MBLs),
include New Delhi MBL (NDM), a novel MBL ﬁrst reported in
Klebsiella pneumoniae and Escherichia coli in New Delhi. The
emergence and dissemination of NDM-1-producing isolates in
both human and environment have been reported in relevant
bacteria and many countries, causing a serious threat for anti-
microbial therapy [2]. Although A. baumannii–c complex is theEuropean Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
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of carbapenemase genes has occurred also in other Acineto-
bacter spp. in the last decade [3,4]. Several reports evidenced
presence of different types of MBL in A. pittii, A. nosocomialis and
A. bereziniae in Korea since 2006 [5]. On the other hand, an
A. baylyi strain carrying both blaSIM-1 and blaOXA-23 was reported
in China in 2011 [6]. Recently, NDM-1 has been detected in
A. soli in Japan, China and Taiwan [7–9], and in other non-
baumannii Acinetobacter spp. in China (Acinetobacter junii, A.
lwofﬁi and A. pittii) [10–12], Turkey and Latin American coun-
tries (A. pittii) [13–15]. These ﬁndings indicate the need for
global surveillance of NDM in Acinetobacter spp.
Resistance rates of imipenem and meropenem in
A. baumannii in Latin America (except for Cuba) in 2004–2010
were reported as 33.6% and 60.6%, respectively, by a large-
scale epidemiological study [16]. The ﬁrst NDM-1-producing
bacterium in Latin America was reported in November 2011
when this enzyme was detected in Klebsiella pneumoniae in
Guatemala [17]. After that, the Pan-American Health Organi-
zation issued a regional alert to strengthen the Latin American
surveillance of carbapenemase producers in Gram-negative
rods (http://www2.paho.org/hq/dmdocuments/2010/alertas_
epi_2010_02_julio_carbapenemasas.pdf). In Cuba, a surveil-
lance network for Acinetobacter has been established since
2010, connecting different hospitals to forward clinical isolates
to the National Institute ‘Pedro Kourí’ in Havana for analysis.
In this study, we described prevalence of Acinetobacter spp.
and their phenotype of resistance and genetic characteristics of
carbapenem resistance genes obtained from national surveil-
lance data in Cuba during 2010–2012.Materials and MethodsBacterial isolates
Clinical isolates of Acinetobacter spp. (only one isolate per pa-
tient) from 30 hospitals in ten provinces across the Cuba during
2010–2012 were collected to the National Institute ‘Pedro
Kourí,’ and clinical information of individual patients was also
obtained. Bacterial identiﬁcation was performed by conven-
tional microbiological methods and later conﬁrmed by API
20NE strip (bioMérieux, Marcy l’Etoile, France). For identiﬁ-
cation of a single strain, genetic analysis was used as described
below.
Antimicrobial susceptibility testing
Minimum inhibitory concentration (MIC) against 18 antibiotics
was measured by Etest (bioMérieux), and susceptibility was
judged according to Clinical and Laboratory Standards Institute
guidelines [18], except for rifampin, which was based on aNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artistandard of the French Microbiology Society (http://www.sfm-
microbiologie.org/UserFiles/ﬁles/casfm_2010.pdf). All isolates
with imipenem MIC 16 mg/L were considered potential car-
bapenemase producers and were selected for testing of MBLs
through the imipenem-EDTA double-disc synergy test as well
as molecular detection of carbapenem resistance genes. As a
carbapenem susceptible reference strain, E. coli strain ATCC
25922 was used.
Genetic analysis
For all the carbapenem-resistant isolates, the presence of
blaOXA genes encoding OXA-51-like, OXA-23-like, OXA-24-
like and OXA-58-like enzymes, and blaIMP, blaVIM and blaNDM
was examined by multiplex PCR with speciﬁc primers, as
described previously [19,20]. For phenotypically MBL-positive
isolates, PCR was performed to detect more metalloenzyme
genes blaGIM, blaSIM and blaSPM as described previously [21].
Sequence analysis
For a single strain (CU244) with NDM gene (blaNDM), partial
sequences of 16s rRNA gene, rpoB, rpoB-rpoC and rpoL-rpoB
intergenic regions, and gyrB were determined for species
identiﬁcation. The PCR products were puriﬁed using the
Wizard SV Gel and PCR Clean-up System (Promega, WI, USA).
Nucleotide sequences were determined using the BigDye
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems,
Foster City, CA) on an automated sequencer (ABI PRISM
3130). Sequences of NDM-1 gene and its upstream and
downstream regions were determined with PCR products
ampliﬁed by primers designed based on sequences of A. lwofﬁi
strain WJ10621 plasmid pNDM-BJ01 (GenBank JQ001791).
Search for homology with cognate gene sequences was per-
formed using BLAST software (Basic Local Alignment Search
Tool, http://blast.ncbi.nlm.nih.gov/). Sequences of the CU244
were deposited in the GenBank database under accession
numbers KP347604 to KP347608 (16S rRNA gene, rpoB, rpoB-
rpoC and rpoL-rpoB intergenic regions, and gyrB) and KP347609
(blaNDM-1 cluster).ResultsThrough the national surveillance program for antimicrobial
resistance of Acinetobacter spp. in Cuba for 2-year period
(2010–2012), a total of 500 nonduplicated clinical isolates were
collected. Original specimens of these isolates were respiratory
samples (n = 193, 38.6%), blood (n = 155, 31.1%), skin and soft
tissue (n = 66, 13.1%) surgical wounds (n = 32, 6.4%), catheter
(n = 14, 2.8%), cerebrospinal ﬂuid (n = 13, 2.6%), sputum (n = 7,
1.4%), lochia (n = 5, 1%) and others (n = 15, 3%). Four hundredlf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 52–56
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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patients admitted to different wards, including intensive care
unit (60.2%), neonatology (12%) and surgical (11.4%) wards and
other departments (16.4%). The remaining eight isolates (1.6%)
were derived from community-acquired infections.
A. baumannii–c complex accounted for 96.4% of all the Aci-
netobacter isolates, while frequencies of other species were low
(A. junii 1.6%, A. lwofﬁi 1%, A. haemolyticus 0.8%, A. soli 0.2%). The
antimicrobial resistance of Acinetobacter spp. isolates is shown in
Table 1. Resistance rates were 34–61% to third-generation
cephalosporin, 49–50% to β-lactam/inhibitor combinations,
42–47% to aminoglycosides, 42–44% to carbapenems and 55%
to ciproﬂoxacin. The most susceptible antimicrobial drugs were
colistin, doxycycline and tetracyclin, showing resistance rates of
less than 5%. Multidrug resistance, deﬁned as resistance to
three or more antimicrobial agent groups, was detected in 57%
of the isolates, and 32% of isolates showed extensive drug
resistance (multidrug-resistant isolates plus carbapenem
resistance).
Among the 220 meropenem-nonsusceptible A. baumannii–c
complex isolates, 17% (37 isolates) were revealed to be MBL
producers by the disk diffusion test with EDTA. All the
A. baumannii–c complex organisms were positive for the
intrinsic blaOXA-51-like gene. Among carbapenem-resistant iso-
lates, 75% harboured different blaOXA (OXA-23, 76%; OXA-
24, 18%; OXA-58, 3%; combination of OXA-23 and OXA-24,
3%). PCR performed with primers speciﬁc for IMP- and VIM-
type enzyme genes was negative for all the carbapenem-
resistant isolates. However, the blaNDM gene was detected in
only one isolate (CU244) of non–A. baumannii–c complex.
Among other MBL-positive isolates, metalloenzyme genes
encoding GIM, SIM and SPM were not detected by PCR.TABLE 1. Resistance rates of Acinetobacter spp. in Cuba and
antimicrobial susceptibility (MIC) of A. soli strain CU244
Antimicrobial drug
Resistance rate (%) of
Acinetobacter spp. (n [ 500)
MIC (μg/mL) of
A. soli strain CU244
Piperacillin 54 128
Ticarcillin/clavulanic acid 50 128
Piperacillin–tazobactam 49 128/4
Ceftazidime 61 32
Ceftriaxone 55 64
Cefotaxime 34 64
Imipenem 42 16
Meropenem 44 16
Gentamicin 47 2
Amikacin 42 2
Tetracycline 3 0.016
Doxycycline 4 0.016
Ciproﬂoxacin 55 1
Levoﬂoxacin 17 1
Trimethoprim–
sulphamethoxazole
19 1/19
Aztreonam 50 4
Rifampicin 11 2
Colistin 1 0.125
MIC, minimum inhibitory concentration.
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identical to those of A. baylyi and A. soli (GenBank accession nos.
JQ229812.1 and JX499235.1, respectively). However, partial
rpoB gene (365 bp), rpoB–rpoC intergenic spacer (177 bp),
rpoL–rpoB intergenic spacer (249 bp) and gyrB gene (686 bp)
showed 98–100% identities to those of A. soli, which were
clearly higher than those to A. baylyi (rpoB, 87%; gryB, 85%).
Therefore, CU244 was identiﬁed as A. soli. The NDM gene of
A. soli strain CU244 was identiﬁed as blaNDM-1 by sequencing
analysis. Upstream of the NDM-1 gene, ISAba125 was located,
and genes from bleR to groEL reported for A. lwofﬁi strain
WJ10621 were identiﬁed downstream of blaNDM-1 (Fig. 1). The
sequence of blaNDM-1 and its surrounding regions, determined
for CU244, was identical to that of A. baumannii strain ZW85-1
plasmid pAbNDM-1 (GenBank NC_019985.2), A. lwofﬁi strain
WJ10621 plasmid pNDM-BJ01 (GenBank JQ001791) and A. soli
strain M131 in Taiwan (GenBank JX072963.1). The NDM-1-
producing CU244 strain was resistant to all β-lactams but
showed good susceptibility to other antimicrobial groups
(Table 1), and possessed no OXA genes examined. Table 2
shows the clinical information of the patient infected with
A. soli producing NDM-1 carbapenemase. This patient had risk
factors, such as prolonged hospitalization in an intensive care
unit, an intravenous catheter and underlying disease.DiscussionA. baumannii–c complex is responsible for hospital-acquired
infections and has become one of the most important
healthcare-associated infections in hospitals. This pathogen is
usually associated with multiple antibiotic resistance and few
therapeutic options of effective agents, which was also evi-
denced in the present report from the national surveillance in
Cuba. Together with studies in other countries and interna-
tional studies, it is clear that the frequency of drug-resistant
A. baumannii strains is increasing worldwide [22]. According
to the SENTRY Antimicrobial Surveillance Program in Latin
America (2008–2010) for Gram-negative bacilli, imipenem-
resistant Acinetobacter spp. rates increased from 0–12.6% in
the 1997–1999 period to 50.0–84.9% in 2008–2010 in
Argentina, Brazil and Chile [23]. In our study, resistance rates
to imipenem and meropenem were 42% and 44%, respectively,
which was slightly lower than but comparable to those in other
Latin American countries, suggesting widespread carbapenem
resistance in this region.
The most susceptible antimicrobial drugs to Cuban isolates
were colistin sulphate, doxycycline, tetracycline and rifampicin,
which were considered to be available for therapy. Over the
last decade, the emergence of multidrug resistant Gram-European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 52–56
nses/by-nc-nd/4.0/)
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FIG. 1. Schematic representation of
surroundings of blaNDM-1 in Acinetobacter
soli strain CU244, based on determined
sequence. For groEL, only 50 side partial
sequence was determined.
NMNI Quiñones et al. NDM-1 gene in A. soli in Cuba 55negative bacteria and the lack of new antimicrobial drugs have
led to a revival of polymyxins, especially colistin. This antibiotic
has been reinstated as a key therapeutic option for
carbapenem-resistant organisms, particularly A. baumannii, P.
aeruginosa and carbapenemase-producing Enterobacteriaceae. It
is very important in countries with limited resources where the
tigecycline is not available.
Several mechanisms of carbapenem resistance have been
reported in A. baumannii, including carbapenemase activity, loss
of outer membrane proteins, penicillin-binding protein modiﬁ-
cations and efﬂux pump activities [1]. The main mechanisms are
fundamentally related to the production of acquired
carbapenem-hydrolyzing class D β-lactamases (oxacillinases) of
phylogenetic subgroups OXA-58, OXA-23, OXA-24/40 and
OXA-143 and, less frequently, to the acquisition of
carbapenem-hydrolyzing metallo-β-lactamases such as those of
type IMP or VIM. In recent studies in Latin America, the
presence of OXA-23 (Brazil, Argentina), OXA-24 (Mexico,
Argentina) and OXA-58 (Chile, Bolivia) has been documented
[23,24], with OXA-23 being the most prevalent (63–87%), in
contrast to the low frequencies of the other two oxacillinases
[25–27]. A similar prevalence of class D carbapenemases was
found in Asia-Paciﬁc countries [28]. Although in the present
study a high detection rate of OXA-23 (76%) was observed, it
was of note that 18% of A. baumannii isolates was positive for
blaOXA-24, suggesting that this oxacillinase may be locally spread
in Cuba. In our present study, 17% of carbapenem-resistant
A. baumannii–c complex isolates were found to produce MBL,TABLE 2. Clinical information of a patient infected with
Acinetobacter soli strain CU244
Characteristic Value
Region Holguin, eastern Cuba
Date of isolation January 2011
Ward Intensive care unit
Patient age 42 years
Patient sex M
Specimen Surgical wound
Underlying disease Bladder cancer
Secondary infection Peritonitis
Useful treatments Colistin and amikacin
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artibut they were negative for blaIMP, blaVIM, blaGIM, blaSIM and
blaSPM by PCR. Although these MBL genes were not identiﬁed,
it is conceivable that these strains might have genetic variant of
the known metalloenzyme gene, which is difﬁcult to be
detected by PCR with reported primers, or might have har-
boured a novel MBL gene.
We reported in this study identiﬁcation of NDM-1 in a
carbapenem-resistant A. soli strain CU244 isolated from a
patient hospitalized in an intensive care unit in Cuba. A. soli is
a novel species of Acinetobacter isolated from soil in Korea in
2008 [29]. The presence of blaNDM-1 in A. soli was reported in
Japan (two strains) [7], China (strain TCM341) [8] and Taiwan
(strain M131) [9]. To our knowledge, CU244 is the ﬁrst A. soli
harbouring blaNDM-1detected outside Asia. By BLAST search,
the genetic organization and sequences of NDM-1 gene and
its surrounding genes of CU244 were found to be identical to
that of strain M131 in Taiwan but distinct from the Japanese
and Chinese strains. As is known as a common genetic feature
of NDM-1 gene [30], the insertion sequence ISAba125 and
bleomycin resistance gene were located upstream and
downstream of blaNDM-1 of CU244, respectively, probably as a
part of transposon Tn125, which is considered to be a main
vehicle for dissemination of blaNDM in A. baumannii [31].
Detection of two genetically identical blaNDM-1 clusters in
Cuba and Taiwan in the rare species A. soli suggested rapid
expansion of blaNDM-1from major species (A. baumannii, A.
lwofﬁi) among various Acinetobacter species. To date, only a
few reports have been published for non-baumannii Acineto-
bacter spp. expressing NDM in the Americas (A. pittii in
Paraguay and Brazil) [14,15]; nosocomial infections caused by
non-baumannii Acinetobacter spp. such as A. soli are extremely
rare, and their associated mortality is low [32]. However,
caution regarding acquisition of NDM-1 by non-baumannii
Acinetobacter spp. may be needed, and the importance of
epidemiological surveillance of non–A. baumannii species,
including A. soli, should be emphasized.
In summary, the ﬁrst National Surveillance Program of Aci-
netobacter spp. in Cuba was conducted, and we reported high
prevalence of blaOXA-23 among Acinetobacter spp. and thelf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 52–56
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
56 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIpresence of blaNDM-1 in A. soli. Our ﬁndings indicate a need for
continuous surveillance regarding drug resistance and the
prevalence of the gene or genes responsible for carbapenem
resistance in Acinetobacter.Conﬂict of InterestNone declared.AcknowledgementThis study was supported by a Grant-in-Aid for Scientiﬁc
Research (KAKENHI; grant 26460804) from the Japan Society
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